Matribhumi Samachar English
U.S. FDA grants waiver of application fee for BLA Filing of OST-HER2 Scheduled pre-Marketing Authorisation Application meeting with United Kingdom’s Medicines and Healthcare products Regulatory Agency on December 8, 2025 Scheduled Type C Meeting with United States Food & Drug Administration on December 11, 2025 New York, New York–(Newsfile Corp. …
Read More »OS Therapies to Participate in Spotlight Panel at BioFuture 2025 October 13 11:00am EDT
New York, New York–(Newsfile Corp. – September 19, 2025) – OS Therapies Inc. (NYSE American: OSTX) (“OS Therapies” or “the Company”), a clinical-stage cancer immunotherapy and antibody drug conjugate biotechnology company, today announced that it has been invited to participate in the “Beyond the Cure: The Brave New World of …
Read More »OS Therapies to Report Second Quarter 2025 Financial Results and Provide Business Update on Tuesday, August 19th, 2025
New York, New York–(Newsfile Corp. – August 14, 2025) – OS Therapies Inc. (NYSE American: OSTX) (“OS Therapies” or “the Company”), a clinical-stage cancer immunotherapy and antibody drug conjugate biotechnology company, today announced that it will report second quarter 2025 financial results ended June 30, 2025 and provide a business …
Read More »